ACOG Updates Uterine Bleeding Recommendations

Fertility Drugs Not Linked to Uterine Cancer Recurrence
Fertility Drugs Not Linked to Uterine Cancer Recurrence
Updated patient management guidelines for the treatment of patients with abnormal uterine bleeding associated with ovulatory dysfunction (AUB-O) have been released.

(HealthDay News) – Updated patient management guidelines for the treatment of patients with abnormal uterine bleeding associated with ovulatory dysfunction (AUB-O) have been released in a practice bulletin published in the July issue of Obstetrics & Gynecology.

The American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology drafted the clinical management guidelines to replace those previously published in March 2000.

Among the committee’s recommendations are: consideration of utilizing levonorgestrel intrauterine device for treatment of AUB in all age groups; possible medical treatment options for AUB-O with progestin therapy and combined hormonal contraception; possible hysterectomy without cervical preservation in women for whom medical therapy failed or is contraindicated and childbearing is complete; and priority consideration should be given to medical rather than surgical treatment.

“The choice of treatment of AUB-O depends on several factors, including the woman’s age, severity of her bleeding, her medical risk factors, her need for contraception, and her desire for future fertility,” the authors write.

Abstract
Full Text (subscription or payment may be required)